Abstract

Huntingtin proteolysis has been implicated in the molecular pathogenesis of Huntington disease (HD). Despite an intense effort, the identity of the pathogenic smallest N-terminal fragment has not been determined. Using a panel of anti-huntingtin antibodies, we employed an unbiased approach to generate proteolytic cleavage maps of mutant and wild-type huntingtin in the HdhQ150 knock-in mouse model of HD. We identified 14 prominent N-terminal fragments, which, in addition to the full-length protein, can be readily detected in cytoplasmic but not nuclear fractions. These fragments were detected at all ages and are not a consequence of the pathogenic process. We demonstrated that the smallest fragment is an exon 1 huntingtin protein, known to contain a potent nuclear export signal. Prior to the onset of behavioral phenotypes, the exon 1 protein, and possibly other small fragments, accumulate in neuronal nuclei in the form of a detergent insoluble complex, visualized as diffuse granular nuclear staining in tissue sections. This methodology can be used to validate the inhibition of specific proteases as therapeutic targets for HD by pharmacological or genetic approaches.

Highlights

  • Disorders, Amgen Inc., Thousand Oaks, California 91320, the **Buck Institute for Age Research, Novato, California 94945, the ‡‡Institut de Genetique et de Biologie Moleculaire et Cellulaire, CNRS/INSERM/Uds, 67404 Illkirch Cedex, France, and the §§Department of Medicine, University of Tennessee Graduate School of Medicine, Knoxville, Tennessee 37920

  • Nuclear inclusions can be readily detected by immunohistochemistry in the cerebral cortex, striatum, and hippocampus by 3 weeks of age [5, 6], Rotarod impairment is apparent by 6 weeks, and end-stage disease occurs at 15 weeks

  • In our homozygous HdhQ150 (HdhQ150/Q150) colony, nuclear inclusions were detected by immunohistochemistry in the striatum and hippocampus by 6 months and the cortex by 8 months, an impaired Rotarod performance was apparent by 18 months of age, and end stage disease occurs at around 22 months [8]

Read more

Summary

Introduction

Digestion of lysates from a single Hdhϩ/Q150 brain aged 2 months with calpain-I and calpain-II indicated that Fragment 7 terminates at a previously unidentified calpain cleavage site that would map between amino acid 488 and 633 in the mouse protein (510 – 654 in human Htt with 23Q) (Fig. 4, A and B). Immunoprecipitation of N-terminal fragments with S830 and immunodetection with MW1 indicated that Fragments 12–14 could not be readily detected in whole brain lysates from Hdhϩ/Q150 mice aged 12 and 21 months (Fig. 5A).

Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call